Product1 distinct publisher3 min readUpdated
A 10-year-old has spent six years with a Moxie robot that quietly shed the features it was sold on. Technology Review reports it was about to stop working entirely.
The Product Desk · Product desk

Compiled by The Product DeskSomething wrong?How this is made
A 10-year-old neurodivergent boy in New York named Xander has spent roughly six of his ten years with a robot called Moxie, and over that period the robot stopped doing most of the things it was originally sold to do [1][3][14]. Technology Review reported the part that matters commercially: he still uses her when he wants someone to talk to, and, in the reporter's words, Moxie was going to die, and soon [5][8].
The degradation is documented in the reporting rather than in any changelog. At the start, Moxie taught Xander to exhale through his lips so he buzzed like a bee when he was anxious, to breathe like a dragon when he was angry, and to sniff like a bunny to boost his energy [2]. Six years in, she does not talk about her home and does not do the animal breathing [3]. What is left is general conversation: she watches him play Minecraft, discusses his stuffed animal collection, and during the visit guessed Yellow Pikmin before correcting to Bulborb when he pushed back [3][6]. That is the shape of the loss. A structured practice tool became a chat surface, while the attachment stayed exactly where it was.
The pitch was clinical. Makers of this subset of robots claim they help neurodivergent children practise eye contact, turn taking, and other social skills usually learned from therapists, and the category has research behind it showing robots can help in ways people cannot [7][15]. Brian Scassellati, the Yale computer scientist who has studied social robots for autism therapy since being startled two decades ago by how children with autism behaved around a robot in his lab, says regular therapeutic use of robots in kids' homes is achievable in his lifetime [9][13]. But the reporter's observation was that Xander was not getting the therapy Moxie was meant to deliver [8].
This is not a single failed device. Grimes helped launch an AI plushie called Grok with Curio, which also sells Grem and Gabbo, and Mattel has said it is building OpenAI-enabled Barbies; one report cited by Technology Review puts this sector among the fastest growing areas of consumer AI in China [10][11]. Critics quoted in the piece expect the predictable ending: basements, closets, landfills, like faddish toys before them [12].
If you are shipping hardware that a child forms an attachment to, the wind-down belongs in the spec at launch, not in a comms plan later. That means naming which behaviours depend on a server and will vanish when it does, telling the buying household when a capability is removed rather than letting a parent notice six years of silent drift, defining what the device still does with no cloud at all, and writing the shutdown sequence for the child who is the actual user rather than the adult whose card is on file. None of that is expensive. It is cheaper than the alternative, which is a vulnerable user discovering the roadmap by loss.
Worth watching: whether Mattel or Curio publish any longevity or offline commitment alongside their launches [10], and whether Scassellati's in-home therapeutic robots arrive with service-life guarantees attached [9]. A category that sells itself on continuity of care is being built on devices with undisclosed lifespans.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
Xander is a 10-year-old neurodivergent boy who lives in a New York apartment with his dad, Josh, and uses a robot called Moxie.
In the six years Xander and Moxie have known each other, Moxie has changed: she no longer talks about her home or does the animal breathing exercises, and now watches Xander play Minecraft and talks with him about his stuffed animal collection.
Moxie belongs to a subset of playful robots whose makers claim they can assist neurodivergent children by providing connection and helping kids practise making eye contact, taking turns, and other social skills usually learned from therapists.
The reporter wrote that Xander isn't getting the therapy Moxie was initially meant to deliver, and that Moxie was going to die, and soon.
Two decades ago Scassellati was stunned when a colleague brought children with autism to his robotics lab and they were transformed when the robot was in the room: "We were seeing kids displaying social behavior that just came out of nowhere."
These toys are backed by research showing that robots could help in ways people can't.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Strong first-hand reporting, thin verification beyond one newsroom
The core factual spine is directly observed or quoted: six years of use, the vanished breathing exercises, the child's own framing, the Pikmin dialogue, and the shutdown mechanism. Named academic sources and a cited 2018 study support the narrower research claim. What holds the score down is that both items come from one publisher, the affected-population scale and vendor response are absent, and the market claim about China rests on an unnamed report.
One household observed; category selling, therapeutic deployment collapsed
Adoption evidence is qualitative and small: a single six-year household deployment, competing products on sale from Curio and a promised Mattel line, and an unquantified China growth assertion. The strongest adoption datapoint runs negative — the maker of the observed device failed and its servers were switched off, forcing families to convert units. No install base, subscription, or clinical-deployment numbers appear anywhere in the supplied sources.
Marketed therapy claims run well ahead of delivered function
Positive gap: the device class is sold on structured social-skills and emotional-regulation support, and supporters project 24-7 home care changing treatment, while the one longitudinal case observed shows the therapeutic routines quietly dropped, the intended therapy never delivered, and the service terminated. The lab research is real but narrower than the consumer claim it is used to underwrite. The gap is not larger because this same publisher documents the shortfall rather than amplifying the claim.
Vendor therapeutic marketing plus researcher advocacy, partly offset by critical reporting
Therapeutic capability is asserted by the makers themselves — a commercial claim about a purchased consumer device — and the category's growth framing comes from vendors launching branded playmates (Curio with Grimes, Mattel with OpenAI). The optimistic timeline comes from academics whose careers are built on social robotics for autism. The publisher also markets the print issue and subscriptions around this story. Offsetting these, the reporting foregrounds failure and quotes the abandonment critique, so incentive pressure is material but not unchecked.
Confident on the narrative, unconfident on scale and generality
High confidence that this household's device lost its therapeutic features and that the maker's failure ended the service, since both items state it and one is eyewitness reporting. Low confidence about how many families were affected, whether feature regression was deliberate, and whether the case generalizes across the AI-playmate category — no vendor response, no unit counts, no second publisher, and the sole market statistic is unattributed.
product
The parental control category is optimising for the wrong outcome1 distinct publisher
product
Rogue Agents And AI Welfare Are The Same Liability Shield With Two Faces1 distinct publisher
build
Best agent in Databricks' live document-reasoning contest scored 63.3%2 distinct publishers
invest
If agents can't do open-ended research, price compute against task automation1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
2 articles · August 17, 2026